Oppenheimer & Co’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.7M Sell
259,210
-23,835
-8% -$3.14M 0.35% 51
2026
Q1
$39.4M Buy
283,045
+14,941
+6% +$2.09M 0.48% 36
2025
Q4
$32.9M Sell
268,104
-25,216
-9% -$3.06M 0.47% 32
2025
Q3
$32.6M Sell
293,320
-4,137
-1% -$470K 0.4% 34
2025
Q2
$33M Buy
297,457
+7,231
+2% +$770K 0.44% 31
2025
Q1
$32.5M Buy
290,226
+3,883
+1% +$401K 0.49% 29
2024
Q4
$26.4M Buy
286,343
+1,835
+0.6% +$165K 0.39% 38
2024
Q3
$23.9M Sell
284,508
-3,964
-1% -$302K 0.36% 46
2024
Q2
$19.8M Sell
288,472
-7,259
-2% -$484K 0.31% 60
2024
Q1
$21.7M Sell
295,731
-3,299
-1% -$254K 0.36% 52
2023
Q4
$24.2M Sell
299,030
-33,399
-10% -$2.6M 0.45% 32
2023
Q3
$24.9M Sell
332,429
-8,124
-2% -$625K 0.51% 28
2023
Q2
$26.2M Sell
340,553
-8,060
-2% -$643K 0.53% 26
2023
Q1
$28.9M Sell
348,613
-2,707
-0.8% -$224K 0.61% 18
2022
Q4
$30.2M Sell
351,320
-66,527
-16% -$5.27M 0.69% 18
2022
Q3
$25.8M Buy
417,847
+24,461
+6% +$1.54M 0.6% 20
2022
Q2
$24.3M Sell
393,386
-5,455
-1% -$338K 0.52% 27
2022
Q1
$23.7M Sell
398,841
-30,819
-7% -$1.97M 0.43% 36
2021
Q4
$31.2M Sell
429,660
-22,549
-5% -$1.55M 0.55% 20
2021
Q3
$31.6M Buy
452,209
+34,814
+8% +$2.45M 0.59% 20
2021
Q2
$28.7M Buy
417,395
+66,644
+19% +$4.45M 0.52% 23
2021
Q1
$22.7M Buy
350,751
+11,440
+3% +$738K 0.45% 35
2020
Q4
$19.8M Sell
339,311
-51,023
-13% -$3.08M 0.42% 46
2020
Q3
$24.7M Sell
390,334
-7,567
-2% -$525K 0.62% 22
2020
Q2
$30.6M Sell
397,901
-33,803
-8% -$2.59M 0.79% 16
2020
Q1
$32.3M Buy
431,704
+51,611
+14% +$3.57M 0.98% 11
2019
Q4
$24.7M Sell
380,093
-5,506
-1% -$359K 0.61% 29
2019
Q3
$24.4M Sell
385,599
-9,444
-2% -$617K 0.67% 26
2019
Q2
$26.7M Sell
395,043
-1,284
-0.3% -$84.5K 0.73% 20
2019
Q1
$25.8M Sell
396,327
-15,485
-4% -$1.03M 0.69% 24
2018
Q4
$25.8M Sell
411,812
-3,343
-0.8% -$234K 0.81% 18
2018
Q3
$32.1M Buy
415,155
+1,984
+0.5% +$150K 0.82% 15
2018
Q2
$29.3M Sell
413,171
-601,960
-59% -$42.5M 0.79% 14
2018
Q1
$76.5M Buy
1,015,131
+13,153
+1% +$1.05M 1.97% 2
2017
Q4
$71.8M Sell
1,001,978
-2,175
-0.2% -$165K 1.85% 2
2017
Q3
$81.4M Sell
1,004,153
-21,297
-2% -$1.63M 2.18% 2
2017
Q2
$72.6M Buy
1,025,450
+8,471
+0.8% +$564K 2% 2
2017
Q1
$69.1M Sell
1,016,979
-45,697
-4% -$3.21M 1.96% 2
2016
Q4
$76.1M Sell
1,062,676
-54,508
-5% -$4.05M 2.22% 1
2016
Q3
$88.4M Sell
1,117,184
-54,898
-5% -$4.46M 2.58% 1
2016
Q2
$97.8M Sell
1,172,082
-12,419
-1% -$1.1M 2.91% 1
2016
Q1
$109M Sell
1,184,501
-9,478
-0.8% -$855K 3.3% 1
2015
Q4
$121M Buy
1,193,979
+18,496
+2% +$1.92M 3.59% 1
2015
Q3
$115M Buy
1,175,483
+143,338
+14% +$15.9M 3.51% 1
2015
Q2
$121M Buy
1,032,145
+480,773
+87% +$52.5M 3.36% 1
2015
Q1
$54.1M Buy
551,372
+8,253
+2% +$838K 1.47% 3
2014
Q4
$51.2M Sell
543,119
-12,086
-2% -$1.25M 1.47% 3
2014
Q3
$59.1M Sell
555,205
-15,981
-3% -$1.56M 1.76% 3
2014
Q2
$47.4M Buy
571,186
+22,843
+4% +$1.78M 1.42% 3
2014
Q1
$38.9M Buy
548,343
+12,038
+2% +$944K 1.17% 4
2013
Q4
$40.3M Buy
536,305
+15,165
+3% +$1.06M 1.29% 4
2013
Q3
$32.8M Buy
521,140
+36,913
+8% +$2.21M 1.15% 4
2013
Q2
$24.8M Buy
+484,227
New +$25.2M 0.96% 6

Other funds holding GILD

Oppenheimer & Co's GILD Position: Q2 2026 in Review

Oppenheimer & Co reduced its Gilead Sciences (GILD) stake by 8.4% in Q2 2026, selling an estimated $3.14M and leaving 259,210 shares worth $32.7M. The position accounts for 0.35% of the portfolio, ranked #51.

Oppenheimer & Co first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $121M in Q2 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Oppenheimer & Co held 259,210 shares of Gilead Sciences worth $32.7M as of Q2 2026.
  • Oppenheimer & Co sold 23,835 Gilead Sciences shares in Q2 2026, an estimated $3.14M.
  • Gilead Sciences made up 0.35% of Oppenheimer & Co's portfolio in Q2 2026, its #51 holding.
  • Oppenheimer & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Oppenheimer & Co's Gilead Sciences position peaked at $121M in Q2 2015.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.